EXOSOMES have lately grown in popularity amongst scientists, physicians, and patients. They are quickly becoming the therapy of choice for those who look to benefit from regenerative therapies.


Exosomes are not cells or tissue.  They are tiny vesicles or “bubbles” produced inside the stem cells and later released. They contain a powerful “cargo” of genetic material, RNA, DNA, peptides, proteins and metabolites. Exosomes communicate with “target” tissues cells, to deliver their “cargo” and tell them when, how and what to do, in order to begin the repair process.

Patients suffering from chronic inflammation, chronic degenerative disease or autoimmune disease could benefit from human Mesenchymal Stem Cells (MSC)-derived exosomes in their treatment regimen.

Because of their tiny size (40 to 100 nm), exosomes can freely enter the human brain, providing an unprecedented healing opportunity for neurodegenerative or brain disease therapy..


A human Mesenchymal Stem Cells (MSC)-derived exosomes therapy is a same-day therapy, usually done in our clinic. The therapy application can be topical or local, intravenous (IV) injection or drip, and intranasal spray. In cases of intrathecal or intradiscal therapy, general anesthesia and exosomes application may be provided at a same-day ambulatory setting.

  • Our exosomes are an allograft material of mesenchymal stem cells-derived exosomes obtained from human placentas. All exosomes administered to our patients are produced in the U.S. by Kimera Laboratories in a concentration of 1 to 3 billion per each milliliter.
  • The fact that exosomes are readily available for therapy at any time or can be stored as an "off-the-shelf" product is a significant advantage over using stem cells.